Health
GSK’s Long-Acting HIV Preventive Drug Is Safe in Pregnant Women
- Rivalry with Gilead in long-acting prevention market heats up
- Gilead to release data from preventive given every six months
This article is for subscribers only.
GSK Plc’s long-acting HIV prevention drug is as safe in pregnant women as daily pills, a boost to the company’s efforts to cement its place in the market for antivirals that patients don’t have to take each day.
Pregnancy outcomes were similar among women who took the drug, called Apretude, and those who took daily antiviral pills, UK-based GSK said Tuesday in a statement. The drug has already been approved for prevention in other adults, and the company will seek to expand the label to include pregnant women.